Which laboratory tests should be obtained to evaluate hyperkalemia?

Laboratory Evaluation of Hyperkalemia

When evaluating hyperkalemia, obtain serum potassium measurement as the primary diagnostic test, followed by an electrocardiogram (ECG) to assess cardiac risk, and then additional labs including renal function tests (creatinine, BUN), urinary potassium excretion, and arterial blood gas to determine the underlying cause. 1, 2

Essential Initial Laboratory Tests

Serum Potassium Measurement

• Serum or plasma potassium concentration is the cornerstone diagnostic test, with hyperkalemia defined as K+ >5.0 mEq/L 2
• Severity classification guides urgency: mild (>5.0 to <5.5 mEq/L), moderate (5.5 to 6.0 mEq/L), and severe (>6.0 mEq/L) 2
• Repeat measurement is critical to exclude pseudohyperkalemia, which results from potassium release during blood sampling or hemolysis 2
• If pseudohyperkalemia is suspected, obtain an arterial sample or ensure proper venous sampling technique 2
• Point-of-care potassium testing can provide rapid results in emergency settings, though laboratory confirmation remains definitive 3, 4

Electrocardiogram (ECG)

• ECG is essential for risk stratification despite variable sensitivity, as it identifies life-threatening cardiac manifestations 1
• Classic findings include peaked T waves and prolonged QRS complexes, though ECG changes can be highly variable and nonspecific 1
• The REVEAL-ED study demonstrated that ECG findings are not as sensitive as laboratory testing for predicting hyperkalemia complications, but remain recommended for determining cardiac risk 1

Diagnostic Workup to Determine Etiology

Renal Function Assessment

• Measure serum creatinine and blood urea nitrogen (BUN) to evaluate kidney function, as hyperkalemia incidence increases with severity of renal impairment 2, 5
• Hyperkalemia occurs in up to 73% of patients with advanced chronic kidney disease 2

Urinary Studies

• Obtain urine potassium, creatinine, and osmolarity as a first step in determining the cause, which directs long-term treatment 5
• These tests help differentiate between decreased renal excretion versus transcellular shifts 6
• Urinary potassium excretion assessment identifies whether the kidneys are appropriately responding to hyperkalemia 6

Acid-Base Status

• Arterial blood gas or venous blood gas helps identify metabolic acidosis, which can contribute to potassium shifts from intracellular to extracellular space 1, 6
• Metabolic acidosis promotes K+ release into the blood and may require specific treatment with sodium bicarbonate 1

Monitoring Frequency Based on Risk Factors

High-Risk Patients Requiring Frequent Monitoring

• Measure serum K+ within 7-10 days after starting or increasing doses of RAASi therapy (ACE inhibitors, ARBs, mineralocorticoid receptor antagonists) 1, 2
• Patients with CKD, diabetes, heart failure, or history of hyperkalemia require more frequent monitoring 1
• Individualized monitoring frequency should be based on comorbidities and concurrent medications that affect potassium homeostasis 1

Chronic Hyperkalemia Assessment

• Repetitive consecutive measurements are necessary to determine whether hyperkalemia is chronic or transient 1
• Chronic or recurrent hyperkalemia is defined as K+ levels >5 mEq/L repetitively measured over a 1-year period 2
• There is no consensus on the exact number of tests required to document chronic hyperkalemia risk 1

Common Pitfalls to Avoid

• Do not rely solely on ECG findings, as they can be absent even with severe hyperkalemia, particularly in patients with CKD, diabetes, or heart failure who may tolerate K+ levels up to 6 mEq/L without arrhythmias 2
• Always rule out pseudohyperkalemia before initiating aggressive treatment, especially if clinical presentation doesn't match laboratory values 2
• Review medication list systematically for drugs that decrease potassium excretion (RAASi, potassium-sparing diuretics, NSAIDs, beta-blockers, trimethoprim-sulfamethoxazole) or increase intake (potassium supplements, salt substitutes) 2
• Consider hyporeninemic hypoaldosteronism in diabetic patients with nephropathy presenting with hyperkalemia 5